Status: Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
Participants needed: 159
Trial details
Phase: Phase 2Age: 5-40Biological sex: AllType: InterventionalSponsor: SAb Biotherapeutics, Inc.Updated: May 29, 2026Locations: 71
Eligibility criteria
Participant and/or appropriate legal guardian must have given written informed c... [+16]
Participant has known allergy, hypersensitivity or moderate to severe allergic r... [+24]